Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 138

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 4
Chunk 138
---
, for example, Palmitoylethanolamide (“ PEA”) and methods for their use in a variety
of indications amenable to treatment, including, but not limited to post-traumatic stress disorder (PTSD), anxiety, and eating disorders.

Compositions comprising LYSERGIC ACID DIETHYLAMIDE
and N-acylethanolamines and uses thereof is a patent family filed on February 10, 2023, as part of our cooperation agreement with SciSparc.
The invention disclosed therein is directed to compositions and methods for potentiating therapeutic effects and/or reducing side-effects
of lysergic acid diethylamide (LSD). The patent application provides pharmaceutical compositions and combinations comprising LSD and N-acylethanolamines,
and methods for their use in a variety of indications amenable to treatment, including, but not limited to, depression, anxiety, headaches,
alcoholism, and pain.

Compositions comprising KETAMINE and N-acylethanolamines
and uses thereof is a patent family filed on February 15, 2023, as part of our cooperation agreement with SciSparc. The patent application
relates to compositions and methods for potentiating therapeutic effects and/or reducing side-effects of ketamine. The patent application
provides pharmaceutical compositions and combinations comprising ketamine and N-acylethanolamines, for example, Palmitoylethanolamide
(“ PEA”) and methods for their use in a variety of indications amenable to treatment, including, but not limited to depression,
suicidal ideation, bipolar disorder, seizures, and pain.

Compositions comprising IBOGAINE and N-acylethanolamines
and uses thereof is a patent family filed on February 15, 2023, as part of our cooperation agreement with SciSparc. The patent application
relates to compositions and methods for potentiating therapeutic effects and/or reducing side-effects of ibogaine. The patent application
provides pharmaceutical compositions and combinations comprising ibogaine and N-acylethanolamines for example, Palmitoylethanolamide (“ PEA”)
and methods for their use in a variety of indications amenable to treatment, including, but not limited to substance addiction and opioid
dependence.

Compositions comprising PSILOCYBIN and N-acylethanolamines
and uses thereof is a patent family filed on February 10, 2023, as part of our cooperation agreement with SciSparc